Do benefits restrictions limit Medicaid acceptance in addiction treatment? Results from a national study
- PMID: 29471926
- PMCID: PMC5826552
- DOI: 10.1016/j.jsat.2018.01.010
Do benefits restrictions limit Medicaid acceptance in addiction treatment? Results from a national study
Abstract
Objective: To assess the relationship of restrictions on Medicaid benefits for addiction treatment to Medicaid acceptance among addiction treatment programs.
Data sources: We collected primary data from the 2013-2014 wave of the National Drug Abuse Treatment System Survey.
Study design: We created two measures of benefits restrictiveness. In the first, we calculated the number of addiction treatment services covered by each state Medicaid program. In the second, we calculated the total number of utilization controls imposed on each service. Using a mixed-effects logistic regression model, we estimated the relationship between state Medicaid benefit restrictiveness for addiction treatment and adjusted odds of Medicaid acceptance among addiction treatment programs.
Data collection: Study data come from a nationally-representative sample of 695 addiction treatment programs (85.5% response rate), representatives from Medicaid programs in forty-seven states and the District of Columbia (response rate 92%), and data collected by the American Society for Addiction Medicine.
Principal findings: Addiction treatment programs in states with more restrictive Medicaid benefits for addiction treatment had lower odds of accepting Medicaid enrollees (AOR = 0.65; CI = 0.43, 0.97). The predicted probability of Medicaid acceptance was 35.4% in highly restrictive states, 48.3% in moderately restrictive states, and 61.2% in the least restrictive states.
Conclusions: Addiction treatment programs are more likely to accept Medicaid in states with less restrictive benefits for addiction treatment. Program ownership and technological infrastructure also play an important role in increasing Medicaid acceptance.
Keywords: Addiction treatment; Health policy; Medicaid.
Copyright © 2018 Elsevier Inc. All rights reserved.
Figures


Similar articles
-
Impact of Medicaid Restrictions on Availability of Buprenorphine in Addiction Treatment Programs.Am J Public Health. 2019 Mar;109(3):434-436. doi: 10.2105/AJPH.2018.304856. Epub 2019 Jan 24. Am J Public Health. 2019. PMID: 30676789 Free PMC article.
-
Factors related to Medicaid payment acceptance at outpatient substance abuse treatment programs.Health Serv Res. 2011 Apr;46(2):632-53. doi: 10.1111/j.1475-6773.2010.01206.x. Epub 2010 Nov 24. Health Serv Res. 2011. PMID: 21105870 Free PMC article.
-
Availability of Outpatient Addiction Treatment and Use of Emergency Department Services Among Medicaid Enrollees.Psychiatr Serv. 2018 Jun 1;69(6):729-732. doi: 10.1176/appi.ps.201700413. Epub 2018 Apr 26. Psychiatr Serv. 2018. PMID: 29695224 Free PMC article.
-
Insurance Receipt and Readiness for Opportunities under the Affordable Care Act: A National Survey of Treatment Providers for Substance Use Disorders.J Psychoactive Drugs. 2017 Apr-Jun;49(2):141-150. doi: 10.1080/02791072.2017.1306661. Epub 2017 Apr 13. J Psychoactive Drugs. 2017. PMID: 28406363
-
Drug treatment program ownership, Medicaid acceptance, and service provision.J Subst Abuse Treat. 2012 Mar;42(2):116-24. doi: 10.1016/j.jsat.2011.10.007. Epub 2011 Dec 5. J Subst Abuse Treat. 2012. PMID: 22154032
Cited by
-
Community coalition and key stakeholder perceptions of the community opioid epidemic before an intensive community-level intervention.J Subst Abuse Treat. 2022 Jul;138:108731. doi: 10.1016/j.jsat.2022.108731. Epub 2022 Jan 31. J Subst Abuse Treat. 2022. PMID: 35125253 Free PMC article. Clinical Trial.
-
A Public Health Strategy for the Opioid Crisis.Public Health Rep. 2018 Nov/Dec;133(1_suppl):24S-34S. doi: 10.1177/0033354918793627. Public Health Rep. 2018. PMID: 30426871 Free PMC article.
-
Medicaid Expansion and Low-Income Adults with Substance Use Disorders.J Behav Health Serv Res. 2021 Jul;48(3):477-486. doi: 10.1007/s11414-020-09738-w. Epub 2020 Nov 6. J Behav Health Serv Res. 2021. PMID: 33156464 Free PMC article.
-
Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA.Neurotherapeutics. 2020 Jan;17(1):55-69. doi: 10.1007/s13311-019-00814-4. Neurotherapeutics. 2020. PMID: 31907876 Free PMC article. Review.
-
Impact of Medicaid Restrictions on Availability of Buprenorphine in Addiction Treatment Programs.Am J Public Health. 2019 Mar;109(3):434-436. doi: 10.2105/AJPH.2018.304856. Epub 2019 Jan 24. Am J Public Health. 2019. PMID: 30676789 Free PMC article.
References
-
- American Society of Addiction Medicine (ASAM) The ASAM Criteria. 2016 Retrieved from: http://www.asam.org/quality-practice/guidelines-and-consensus-documents/....
-
- American Society of Addiction Medicine (ASAM) Advancing access to addiction medications: Implications for opioid addiction treatment. 2013 Retrieved from: http://www.asam.org/docs/default-source/advocacy/aaam_implications-for-o....
-
- Andrews CM, Shin HC, Marsh JC, Cao D. Client and program characteristics associated with wait time to substance abuse treatment entry. The American Journal Drug and Alcohol Abuse, Early Online. 2012:e1–8. - PubMed
-
- Andrews CM. The relationship of state Medicaid coverage to Medicaid acceptance among substance providers in the United States. Journal of Behavioral Health Services & Research. 2014:1–12. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical